PuraPharm Corp. Ltd. (HK:1498) has released an update.
PuraPharm Corporation Limited reported an overall revenue increase of 6.4% to HK$207.627 million for the first half of 2024 compared to the same period in 2023, despite a notable decrease in their China CCMG segment and a significant reduction in loss by 50.4%. The company saw substantial growth in their Chinese healthcare products and Nong’s medicine clinics, with plantation revenue experiencing the highest surge. However, the group still incurred a loss for the period, although the loss per share decreased from HK cents 9.54 to 4.73.
For further insights into HK:1498 stock, check out TipRanks’ Stock Analysis page.
